Cardiotoxicity of Chemotherapeutic Agents

[1]  S. Legha,et al.  Neurologic and cardiac rhythm abnormalities associated with 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) therapy. , 1979, Cancer treatment reports.

[2]  J. Doroshow,et al.  Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. , 1980, The Journal of clinical investigation.

[3]  J. Hannigan,et al.  Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. , 1986, Cancer research.

[4]  B. Cazin,et al.  Cardiac complications after bone marrow transplantation. A report on a series of 63 consecutive transplantations , 1986, Cancer.

[5]  P. Hekali,et al.  Cardiac involvement in bone marrow transplantation: electrocardiographic changes, arrhythmias, heart failure and autopsy findings. , 1990, Bone marrow transplantation.

[6]  R. Benjamin,et al.  Phase 1 clinical investigation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992), a new acridine derivative. , 1978, Cancer research.

[7]  A. Bast,et al.  Isolated mouse atrium as a model to study anthracycline cardiotoxicity: the role of the beta-adrenoceptor system and reactive oxygen species. , 1990, Research communications in chemical pathology and pharmacology.

[8]  D. V. Von Hoff,et al.  Cardiotoxicity in patients treated with mitoxantrone: Southwest Oncology Group phase II studies. , 1987, Cancer treatment reports.

[9]  T. Schulte.  [Lethal intoxication with leaves of the yew tree (Taxus baccata) (author's transl)]. , 1975, Archives of toxicology.

[10]  S K Carter,et al.  Adriamycin. A new anticancer drug with significant clinical activity. , 1974, Annals of internal medicine.

[11]  T. Pajak,et al.  Adriamycin given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity. , 1980, Cancer treatment reports.

[12]  D. Rosenthal,et al.  Combination chemotherapy of advanced non-Hodgkin lymphoma with bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP). , 1977, Blood.

[13]  C. Patte,et al.  High-dose busulfan and cyclophosphamide with autologous bone marrow transplantation support in advanced malignancies in children: a phase II study. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Talpaz,et al.  Vindesine-associated angina and ECG changes. , 1982, Cancer treatment reports.

[15]  E. Estey,et al.  Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). , 1992, Blood.

[16]  Y. Tekol.  Negative Chronotropic and Atrioventricular Blocking Effects of Taxine on Isolated Frog Heart and Its Acute Toxicity in Mice , 1985, Planta medica.

[17]  R. Silver,et al.  Phase I-II trial of mitoxantrone in acute leukemia. , 1985, Cancer treatment reports.

[18]  A. Mittelman,et al.  Renal toxicity in man treated with mitomycin C , 1971, Cancer.

[19]  C. Coltman,et al.  Acute ventricular fibrillation and death during infusion of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA). , 1980, Cancer treatment reports.

[20]  R. Labianca,et al.  Cardiac Toxicity of 5-Fluorouracil: A Study on 1083 Patients , 1982, Tumori.

[21]  T. N. James,et al.  Chronotropic and dromotropic effects of histamine on the canine heart. , 1979, Chest.

[22]  S. Giri,et al.  Effects of chronic administration of doxorubicin on myocardial beta-adrenergic receptors. , 1986, Life sciences.

[23]  M. Shah,et al.  An effective low‐dose mitomycin regimen for hormonal‐ and chemotherapy‐refractory patients with metastatic breast cancer , 1983, Cancer.

[24]  Thomas D. Giles,et al.  Consensus recommendations for the management of chronic heart failure: Introduction , 1999 .

[25]  Rosenfeld Cs,et al.  Cisplatin-induced autonomic neuropathy. , 1984 .

[26]  J. Hainsworth,et al.  Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. , 1986, Annals of internal medicine.

[27]  J. Verweij,et al.  Mitomycin C-induced hemolytic uremic syndrome. Six case reports and review of the literature on renal, pulmonary and cardiac side effects of the drug. , 1987, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[28]  G. Decorti,et al.  Characterization of histamine secretion induced by anthracyclines in rat peritoneal mast cells. , 1986, Biochemical pharmacology.

[29]  J. Ornato,et al.  Guidelines for cardiopulmonary resuscitation and emergency cardiac care, III: Adult advanced cardiac life support , 1992 .

[30]  F. Muggia,et al.  Doxorubicin-cyclophosphamide: effective chemotherapy for advanced endometrial adenocarcinoma. , 1977, American journal of obstetrics and gynecology.

[31]  J. Bernaudin,et al.  Pulmonary edema and shock after high-dose aracytine-C for lymphoma; possible role of TNF-alpha and PAF. , 1993, European cytokine network.

[32]  S. Crooke,et al.  Mitomycin C. , 1976, IARC monographs on the evaluation of the carcinogenic risk of chemicals to man.

[33]  D. Harrison,et al.  Histamine and the human heart: the other receptor system. , 1982, The American journal of cardiology.

[34]  Daniels,et al.  Clinical spectrum of anthracycline antibiotic cardiotoxicity. , 1978, Cancer treatment reports.

[35]  P. Kouides,et al.  Cytarabine-induced pericarditis: a case report and review of the literature of the cardio-pulmonary complications of cytarabine therapy. , 1995, Leukemia research.

[36]  A. Blum.  Nicotine chewing gum and the medicalization of smoking. , 1984, Annals of internal medicine.

[37]  M. Djaldetti,et al.  Vincristine‐induced myocardial infarction , 1975, Cancer.

[38]  G. Bonadonna,et al.  Phase II evaluation of adriamycin in human neoplasia , 1973, Cancer.

[39]  R. Levi.  Effects of exogenous and immunologically released histamine on the isolated heart: a quantitative comparison. , 1972, The Journal of pharmacology and experimental therapeutics.

[40]  W. Gradishar,et al.  5-Fluorouracil cardiotoxicity: a critical review. , 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  J. Pinkhas,et al.  Endocardial fibrosis following busulfan treatment. , 1975, JAMA.

[42]  W. Terpstra,et al.  Pericardial fibrosis following busulfan treatment. , 1989, The Netherlands journal of medicine.

[43]  M. Horellou,et al.  L-ASPARAGINASE, ANTITHROMBIN III, AND THROMBOSIS , 1980, The Lancet.

[44]  V. Ferrans,et al.  ACUTE LETHAL CARDITIS CAUSED BY HIGH-DOSE COMBINATION CHEMOTHERAPY A Unique Clinical and Pathological Entity , 1976, The Lancet.

[45]  P. Neiman,et al.  High‐dose cyclophosphamide therapy for malignant disease. Toxicity, tumor response, and the effects of stored autologous marrow , 1972 .

[46]  K. Antman,et al.  Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. , 1985, Cancer treatment reports.

[47]  J. Talcott,et al.  Acute ischemic vascular events and cisplatin. , 1987, Annals of internal medicine.

[48]  E. Bruera,et al.  Vinca alkaloid-induced cardiovascular autonomic neuropathy. , 1985, Cancer treatment reports.

[49]  V. Ferrans,et al.  ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  R. Schneider,et al.  Phase II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in patients with metastatic hypernephroma. , 1980, Cancer treatment reports.

[51]  J. Silber,et al.  Increased risk of cardiac dysfunction after anthracyclines in girls. , 1993, Medical and pediatric oncology.

[52]  M. Grever,et al.  Long-term follow-up of patients with hairy cell leukemia after treatment with 2'-deoxycoformycin. , 1994, Blood.

[53]  H. Bruckner,et al.  Prophylaxis of 5-fluorouracil-induced coronary vasospasm with calcium channel blockers. , 1988, The American journal of medicine.

[54]  M. Coulthard,et al.  Nephrotoxicity after ifosfamide. , 1990, Archives of disease in childhood.

[55]  W. Hiddemann,et al.  Cardiotoxicity of 5‐fluorouracil in combination with folinic acid in patients with gastrointestinal cancer , 1993, Cancer.

[56]  L. Lemaire,et al.  Cardiotoxicity of commercial 5-fluorouracil vials stems from the alkaline hydrolysis of this drug. , 1992, British Journal of Cancer.

[57]  A. Kornberg,et al.  Ventricular fibrillation, hypokalemia, and AMSA therapy. , 1982, Annals of internal medicine.

[58]  D. Karnofsky,et al.  Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia , 1967, Cancer.

[59]  S. Sallan,et al.  Intermittent combination chemotherapy with adriamycin for childhood acute lymphoblastic leukemia: clinical results. , 1978, Blood.

[60]  D. T. Harrison,et al.  Letter: Pericarditis in a case of early daunorubicin cardiomyopathy. , 1976, Annals of internal medicine.

[61]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[62]  E. Hersh,et al.  Evaluation of vindesine and MER in colorectal cancer , 1980, Cancer.

[63]  J. Gottdiener,et al.  Cardiotoxicity associated with high-dose cyclophosphamide therapy. , 1981, Archives of internal medicine.

[64]  V. Devita,et al.  Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. , 1976, Annals of internal medicine.

[65]  D. Higby.  "Pharmacokinetics and immediate effects of high-dose carmustine in man". , 1986, Cancer treatment reports.

[66]  Salmon Se.  Nitrosoureas in multiple myeloma. , 1976 .

[67]  E. Gehan,et al.  Combination therapy for multiple myeloma , 1977, Cancer.

[68]  D. Carson,et al.  Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. , 1990, The New England journal of medicine.

[69]  E. Estey,et al.  Subacute pulmonary failure complicating therapy with high‐dose ara‐C in acute leukemia , 1985, Cancer.

[70]  D. Hossfeld,et al.  TNF-induced cardiomyopathy , 1990, The Lancet.

[71]  E. Estey,et al.  2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. , 1994, Blood.

[72]  V. Devita,et al.  Combination chemotherapy in the treatment of advanced Hodgkin's disease. , 1970, Annals of internal medicine.

[73]  D. V. Von Hoff,et al.  Risk factors for doxorubicin-induced congestive heart failure. , 1979, Annals of internal medicine.

[74]  C Lenfant,et al.  NHLBI funding policies. Enhancing stability, predictability, and cost control. , 1994, Circulation.

[75]  C. Tibaldi,et al.  Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  E. Orwoll,et al.  Interstitial pneumonia from mitomycin. , 1978, Annals of internal medicine.

[77]  R. Levi,et al.  Acceleration of Idioventricular Rhythms by Histamine in Guinea Pig Heart: Mediation by H2 Receptors , 1979, Circulation research.

[78]  D. V. Von Hoff,et al.  Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. , 1977, The American journal of medicine.

[79]  C. Geraci,et al.  Aortic Arteriosclerosis in the Dog After Localized Aortic Irradiation with Electrons , 1962, Circulation research.

[80]  L. M. Glodé,et al.  Unanticipated side effects from treatment with high-dose mechlorethamine in patients with malignant melanoma. , 1981, Cancer treatment reports.

[81]  R. Hawkins,et al.  Cancer - Principles and Practice of Oncology, 5th Edition , 1998, British Journal of Cancer.

[82]  M. Albertsson,et al.  Failure of preventing 5-fluorouracil cardiotoxicity by prophylactic treatment with verapamil. , 1990, Acta oncologica.

[83]  G. Hortobagyi,et al.  Doxorubicin‐induced congestive heart failure in adults , 1985, Cancer.

[84]  J. Lowenstein,et al.  Inhibition of phosphorylation of troponin I in rat heart by adenosine and 5'-chloro-5'-deoxyadenosine. , 1991, Biochemical pharmacology.

[85]  R. J. Cersosimo,et al.  Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  M. Uusitupa,et al.  Cardiotoxicity of epirubicin and doxorubicin: A double‐blind randomized study , 1991, European journal of haematology.

[87]  J. Doroshow.  Effect of anthracycline antibiotics on oxygen radical formation in rat heart. , 1983, Cancer research.

[88]  V. Ratanatharathorn,et al.  Phase II evaluation of 4'-(9-acridinylamino)-methanesulfon-m--anisidine (AMSA) in patients with advanced head and neck cancers. , 1982, American journal of clinical oncology.

[89]  B. Lipworth,et al.  Reversible myocardial ischaemia following vincristine containing chemotherapy. , 1994, Respiratory medicine.

[90]  E. Dmitrovsky,et al.  All-trans Retinoic Acid for Acute Promyelocytic Leukemia: Results of the New York Study , 1994, Annals of Internal Medicine.

[91]  J. Silber,et al.  Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. , 1992, The American journal of cardiology.

[92]  M. Bristow,et al.  Anthracycline-associated cardiac and renal damage in rabbits. Evidence for mediation by vasoactive substances. , 1981, Laboratory investigation; a journal of technical methods and pathology.

[93]  A. Camm,et al.  Signal‐averaged electrocardiography and the significance of late potentials in patients with ‘idiopathic’ ventricular tachycardia: A review , 1989, Clinical cardiology.

[94]  S. Marsoni,et al.  Amsacrine-associated cardiotoxicity: an analysis of 82 cases. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  P. Sager,et al.  Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. , 1987, The American journal of medicine.

[96]  J. Holland,et al.  Biochemical and pharmacological studies with asparaginase in man. , 1970, Cancer research.

[97]  T. Kuzel,et al.  Thrombogenicity of intravenous 5‐fluorouracil alone or in combination with cisplatin , 1990, Cancer.

[98]  P. Schein,et al.  Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[99]  P. Hasleton,et al.  Anthracyclines and the heart. , 1993, British heart journal.

[100]  D. Faulds,et al.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. , 1993, Drugs.

[101]  R. Davis,et al.  cis-Dichlorodiammineplatinum(II) (NSC-119 875): preclinical toxicologic evaluation of intravenous injection in dogs, monkeys and mice. , 1973, Toxicology and applied pharmacology.

[102]  T. Miller,et al.  Extensive adenocarcinoma and large cell undifferentiated carcinoma of the lung treated with 5-FU, vincristine, and mitomycin C (FOMi). , 1980, Cancer treatment reports.

[103]  B. Koczwara,et al.  The development of congestive cardiac failure in a patient with hairy cell leukemia treated with 2-chlorodeoxyadenosine. , 1997, Leukemia & lymphoma.

[104]  H. Schulman,et al.  Cyclophosphamide cardiac injury mimicking acute myocardial infarction. , 1993, Bone marrow transplantation.

[105]  L. Lenaz,et al.  Mitomycin C in advanced breast cancer. , 1985, Cancer treatment reviews.

[106]  A. Weiss,et al.  Experience with the use of adriamycin in combination with other anticancer agents using a weekly schedule, with particular reference to lack of cardiac toxicity , 1977, Cancer.

[107]  E J Orav,et al.  Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. , 1995, The New England journal of medicine.

[108]  S. Chierchia,et al.  Myocardial infarction in a patient with acute lymphoblastic leukemia during L‐asparaginase therapy , 1995, American journal of hematology.

[109]  G. Hutchins,et al.  Ara-C lung: noncardiogenic pulmonary edema complicating cytosine arabinoside therapy of leukemia. , 1981, The American journal of medicine.

[110]  P. Singal,et al.  Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. , 1994, Circulation.

[111]  Norbertus C. Robben,et al.  The syndrome of 5‐fluorouracil cardiotoxicity. An elusive cardiopathy , 1993, Cancer.

[112]  J. Gryn,et al.  Pentostatin increases the acute toxicity of high dose cyclophosphamide. , 1993, Bone Marrow Transplantation.

[113]  P. Steinherz,et al.  Cardiac changes with cyclophosphamide. , 1981, Medical and pediatric oncology.

[114]  M. Tomasz,et al.  The mode of interaction of mitomycin C with deoxyribonucleic acid and other polynucleotides in vitro. , 1974, Biochemistry.

[115]  G. Bonadonna,et al.  Phase II study of doxorubicin versus epirubicin in advanced breast cancer. , 1986, Cancer treatment reports.

[116]  A. Caraceni,et al.  Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[117]  C. Winterbourn,et al.  The hydrolysis product of ICRF-187 promotes iron-catalysed hydroxyl radical production via the Fenton reaction. , 1993, Biochemical pharmacology.

[118]  R. Donehower,et al.  Taxol: a novel investigational antimicrotubule agent. , 1990, Journal of the National Cancer Institute.

[119]  J. Willerson,et al.  Evaluation of free radical effects and catecholamine alterations in adriamycin cardiotoxicity. , 1984, The American journal of pathology.

[120]  C. Coltman,et al.  Phase I clinical investigation of 1,4-dihydroxy-5,8-bis (( (2-[(2-hydroxyethyl)amino]ethyl) amino))-9,10-anthracenedione dihydrochloride (NSC 301739), a new anthracenedione. , 1980, Cancer research.

[121]  J. Moake,et al.  Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. , 1985, Oncology.

[122]  R. Willemze,et al.  High dose cytosine arabinoside in the management of refractory acute leukaemia. , 2009, Scandinavian journal of haematology.

[123]  R. Day,et al.  A randomized phase II study of m‐AMSA (NSC 249992) and neocarzinostatin (NSC 157365) in non‐small cell broncliogenic carcinoma: An Eastern Cooperative Group Study , 1983, American Journal of Clinical Oncology.

[124]  A. Goldhirsch,et al.  Acute cerebrovascular accident after treatment with cis-platinum and methylprednisolone. , 1983, Oncology.

[125]  J. Dobson,et al.  Inhibition by adenosine of catecholamine-induced increase in rat atrial contractility. , 1980, The American journal of physiology.

[126]  M. Weil,et al.  Optimal use of L-asparaginase (NSC-109229) in acute lymphocytic leukemia. , 1977, Medical and pediatric oncology.

[127]  M. Andreeff,et al.  Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[128]  M. Christian,et al.  A reassessment of cardiac toxicity associated with Taxol. , 1993, Journal of the National Cancer Institute. Monographs.

[129]  V. Ferrans,et al.  Cardiac pathologic findings in patients treated with bone marrow transplantation. , 1976, Human pathology.

[130]  J. Srigley,et al.  Radionuclide angiography and endomyocardial biopsy in the assessment of doxorubicin cardiotoxicity , 1984 .

[131]  B. Davidow,et al.  Anaphylaxis; consequence of yew (Taxus) needle ingestion. , 1979, New York state journal of medicine.

[132]  M. J. Ehrke,et al.  Correlation between adriamycin-induced augmentation of interleukin 2 production and of cell-mediated cytotoxicity in mice. , 1986, Cancer research.

[133]  J. Mantle,et al.  Anthracycline-induced cardiomyopathy in children: a report of six cases. , 1984, Medical and pediatric oncology.

[134]  S. Steinberg,et al.  Prospective study of cardiomyopathy induced by adjuvant doxorubicin therapy in patients with soft-tissue sarcomas. , 1986, Archives of surgery.

[135]  M. Goldberg,et al.  Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. , 1986, Blood.

[136]  N. Vogelzang,et al.  Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin , 1985, Cancer.

[137]  B. M. Henderson,et al.  Safety assessment of a new anticancer compound, mitoxantrone, in beagle dogs: comparison with doxorubicin. I. Clinical observations. , 1982, Cancer treatment reports.

[138]  H. von Melchner,et al.  Adriamycin cardiotoxicity: a survey of 1273 patients. , 1979, Cancer treatment reports.

[139]  T. Vietti,et al.  Clinical study of daunomycin and prednisone for induction of remission in children with advanced leukemia. , 1969, The New England journal of medicine.

[140]  T. Ng,et al.  Effect of Adenosine Deaminase Inhibitors on the Heart's Functional and Biochemical Recovery from Ischemia: A Study Utilizing the Isolated Rat Heart Adapted to 31P Nuclear Magnetic Resonance , 1983, Journal of cardiovascular pharmacology.

[141]  C. Pratt,et al.  Fatal congestive heart failure following mitoxantrone treatment in two children previously treated with doxorubicin and cisplatin. , 1983, Cancer treatment reports.

[142]  E. V. Van Scott,et al.  Complete remissions of mycosis fungoides lymphoma induced by topical nitrogen mustard (HN2). Control of delayed hypersensitivity to HN2 by desensitization and by induction of specific immunologic tolerance , 1973, Cancer.

[143]  N. Vogelzang,et al.  Coronary artery disease after treatment with bleomycin and vinblastine. , 1980, Cancer treatment reports.

[144]  H. Ising,et al.  Magnesium deficiency and hypertension: correlation between magnesium-deficient diets and microcirculatory changes in situ. , 1984, Science.

[145]  R. Brookmeyer,et al.  Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. , 1983, The New England journal of medicine.

[146]  R. Ungerleider,et al.  Phase I trial of mitoxantrone in children. , 1985, Cancer treatment reports.

[147]  S. Gardner,et al.  High-dose cyclophosphamide-induced myocardial damage during BMT: assessment by positron emission tomography. , 1993, Bone marrow transplantation.

[148]  W. Panje,et al.  Vascular events in patients receiving high-dose infusional 5-fluorouracil-based chemotherapy: the University of Chicago experience. , 1991, Medical and pediatric oncology.

[149]  R. Gelber,et al.  The impact of induction anthracycline on long-term failure-free survival in childhood acute lymphoblastic leukemia. , 1986, Medical and pediatric oncology.

[150]  R. Olson,et al.  Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[151]  P. Steinherz,et al.  Delayed cardiac toxicity from anthracycline therapy. , 1991, Pediatrician.

[152]  I. Ifrim,et al.  Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. , 1977, Science.

[153]  R. Kloner,et al.  5‐Fluorouracil Cardiotoxicity: Left Ventricular Dysfunction and Effect of Coronary Vasodilators , 1987, The American journal of the medical sciences.

[154]  V. Devita,et al.  Treatment of advanced Hodgkin's disease with (1,3 bis (2-chloroethyl)-1-nitrosourea) BCNU. , 1971, The New England journal of medicine.

[155]  I. Smith,et al.  Mitoxantrone (novantrone): a review of experimental and early clinical studies. , 1983, Cancer treatment reviews.

[156]  P. Steinherz,et al.  Cardiac toxicity 4 to 20 years after completing anthracycline therapy. , 1991, JAMA.

[157]  E. Farber,et al.  Topical therapy of psoriasis with mechlorethamine. , 1972, Archives of dermatology.

[158]  J. Minna,et al.  Phase II clinical trial of weekly administration of VP-16-213 in small cell bronchogenic carcinoma. , 1977, Cancer treatment reports.

[159]  E K Rowinsky,et al.  Cardiac disturbances during the administration of taxol. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[160]  A. Stansfeld,et al.  Combination Chemotherapy in Generalized Hodgkin's Disease , 1970, British medical journal.

[161]  E. Cook,et al.  Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[162]  Riela Ar,et al.  Cardiac arrhythmia associated with AMSA in a child: a Southwest Oncology Group Study. , 1981 .

[163]  C. F. Miller,et al.  Acute ECG changes associated with AMSA treatment. , 1982, Cancer treatment reports.

[164]  T. Shea,et al.  High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[165]  A H Harken,et al.  Relation between late potentials on the body surface and directly recorded fragmented electrograms in patients with ventricular tachycardia. , 1983, The American journal of cardiology.

[166]  M. Iatropoulos,et al.  Safety assessment of new anticancer compound, mitoxantrone, in beagle dogs: comparison with doxorubicin. II. Histologic and ultrastructural pathology. , 1982, Cancer treatment reports.

[167]  D. V. Van Echo,et al.  Combination chemotherapy for small cell carcinoma of the lung: continuous versus alternating non-cross-resistant combinations. , 1982, Cancer treatment reports.

[168]  P. Singal,et al.  Combination therapy with probucol prevents adriamycin-induced cardiomyopathy. , 1995, Journal of molecular and cellular cardiology.

[169]  Richard P. Lewis,et al.  ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). , 1996, Journal of the American College of Cardiology.

[170]  G. Gasparini,et al.  Cardiac Arrhythmia: Possible Complication from Treatment with Cisplatin , 1986, Tumori.

[171]  D. V. Von Hoff,et al.  VM 26 and VP 16–213: A comparative analysis , 1977, Cancer.

[172]  E. Estey,et al.  Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid. , 1996, Leukemia & lymphoma.

[173]  W. Crist,et al.  The cytosine arabinoside (Ara-C) syndrome. , 1981, Medical and pediatric oncology.

[174]  W. Samlowski,et al.  Cardiomyopathy associated with high-dose interleukin-2 therapy. , 1991, The Western journal of medicine.

[175]  B. Leyland-Jones,et al.  Hypersensitivity reactions from taxol. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[176]  J. Blom,et al.  Amputation and adriamycin in primary osteosarcoma. , 1974, The New England journal of medicine.

[177]  R. Donehower,et al.  Drug therapy : paclitaxel (Taxol) , 1995 .

[178]  D. Mikhailidis,et al.  CARDIOTOXICITY OF 5-FLUOROURACIL , 1977, The Lancet.

[179]  G. Hortobagyi,et al.  Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in metastatic breast cancer. , 1979, Cancer treatment reports.

[180]  K M Kessler,et al.  Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure: conflicting results may lead to inappropriate care. , 1991, The American journal of medicine.

[181]  G. Schuurhuis,et al.  Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. , 1990, Pharmacology & therapeutics.

[182]  G. Iacobellis,et al.  5-Fluorouracil cardiotoxicity. , 1990, European Journal of Gynaecological Oncology.

[183]  L. F. Fajardo,et al.  Pathogenesis of radiation-induced myocardial fibrosis. , 1973, Laboratory investigation; a journal of technical methods and pathology.

[184]  D. Mann,et al.  Expression and functional significance of tumor necrosis factor receptors in human myocardium. , 1995, Circulation.

[185]  M. Tomasz.  H2O2 generation during the redox cycle of mitomycin C and dna-bound mitomycin C. , 1976, Chemico-biological interactions.

[186]  M. Conrad.  Cytarabine and Cardiac Failure , 1992, American journal of hematology.

[187]  R. Larson,et al.  HYPERSENSITIVITY REACTION TO HIGH‐DOSE CYTARABINE , 1989, British journal of haematology.

[188]  L. Lemaire,et al.  Fluoroacetaldehyde as cardiotoxic impurity in fluorouracil (Roche) , 1991, The Lancet.

[189]  P. Elwood,et al.  Milk antibodies and myocardial infarction [Letter] , 1974 .

[190]  R. Young,et al.  BCNU (NSC-409962) in the treatment of advanced Hodgkin's disease: its role in remission induction and maintenance. , 1976, Cancer treatment reports.

[191]  P. Tweeddale.  Automatic blood-gas analysers. , 1979, British medical journal.

[192]  M. Rudnick,et al.  Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. , 1984, Annals of internal medicine.

[193]  Bodensteiner Dc.  Fatal coronary artery fibrosis after treatment with bleomycin, vinblastine, and cis-platinum. , 1981 .

[194]  A. Shainberg,et al.  Pathways of adenine nucleotide catabolism in primary rat muscle cultures. , 1987, Biochimica et biophysica acta.

[195]  S. Berliner,et al.  Acute coronary events following cisplatin-based chemotherapy. , 1990, Cancer investigation.

[196]  V. Dilsizian,et al.  Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[197]  P. Steinherz,et al.  Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients. , 1995, Medical and pediatric oncology.

[198]  R. Silver,et al.  Mitoxantrone in patients with acute leukemia in relapse. , 1983, Cancer research.

[199]  M. Abeloff,et al.  Hemolytic-uremic syndrome associated with mitomycin therapy. , 1982, Cancer treatment reports.

[200]  R. K. Knight,et al.  Mitoxantrone in advanced breast cancer--a phase II study with special attention to cardiotoxicity. , 1984, European journal of cancer & clinical oncology.

[201]  D. Dodwell,et al.  Etoposide-related myocardial infarction. , 1995, Clinical oncology (Royal College of Radiologists (Great Britain)).

[202]  Jones Se,et al.  Myocardial infarction in a 27-year-old woman: possible complication of treatemtn with VP-16-213 (NSC-141540), mediastinal irradiation, or both. , 1975, Cancer chemotherapy reports.

[203]  J. Holland,et al.  Amputation and adriamycin in primary osteosarcoma: a 5-year report. , 1978, Cancer treatment reports.

[204]  C. Mercke,et al.  Adverse cardiac effects during induction chemotherapy treatment with cis-platin and 5-fluorouracil. , 1988, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[205]  R. Benjamin,et al.  Phase II study of 4'-(9-acridinylamino) methanesulfon-m- anisidide (AMSA) in metastatic melanoma. , 1980, Cancer clinical trials.

[206]  P. Soulié,et al.  Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[207]  R. Kloner,et al.  Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[208]  A. Serafini,et al.  Review of tests for monitoring doxorubicin-induced cardiomyopathy. , 1996, Oncology.

[209]  S. Lipshultz,et al.  Anthracycline-induced cardiotoxicity in children and young adults. , 1998, Critical reviews in oncology/hematology.

[210]  S. Rajagopalan,et al.  Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity. , 1988, Cancer research.

[211]  J. A. Page,et al.  Cardiotoxicity of adriamycin and related anthracyclines. , 1976, Cancer treatment reviews.

[212]  A. Ross,et al.  Acute arrhythmogenicity of doxorubicin administration , 1987, Cancer.

[213]  M. Grever,et al.  Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[214]  M. Siimes,et al.  Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiation. , 1996, European journal of cancer.

[215]  J. Minna,et al.  Combination chemotherapy with doxorubicin and mitomycin C in non small cell bronchogenic carcinoma: Severe pulmonary toxicity from q 3 weekly mitomycin C , 1984, American journal of clinical oncology.

[216]  F. Ganzina.  4'-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data. , 1983, Cancer treatment reviews.

[217]  B. Leyland-Jones,et al.  Hypersensitivity reactions to teniposide (VM-26): an analysis. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[218]  P. Singal,et al.  Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. , 1995, Circulation.

[219]  W. Evans,et al.  Age-related adriamycin cardiotoxicity in children. , 1978, Cancer treatment reports.

[220]  R. Magorien,et al.  N-acetylcysteine prevents the doxorubicin-induced decrease of cyclic GMP. , 1983, Seminars in oncology.

[221]  G. Milano,et al.  Very high endothelin plasma levels in patients with 5-FU cardiotoxicity. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

[222]  I. Smith,et al.  CARDIOTOXICITY ASSOCIATED WITH - MITOXANTRONE , 1984, The Lancet.

[223]  S. Wallace,et al.  Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. , 1982, Annals of internal medicine.

[224]  J. Blom,et al.  Daunorubicin (NSC 82151) in the treatment of advanced childhood lymphoblastic leukemia. , 1971, Cancer research.

[225]  G. Bodey,et al.  Potential cardiotoxicity with mitoxantrone. , 1982, Cancer treatment reports.

[226]  J. Mason,et al.  Anthracycline cardiomyopathy monitored by morphologic changes. , 1978, Cancer treatment reports.

[227]  T. Godfrey,et al.  Mitomycin C in large infrequent doses in breast cancer. , 1976, Medical and pediatric oncology.

[228]  S. Colan,et al.  Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. , 1991, The New England journal of medicine.

[229]  D. Ettinger,et al.  Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. , 1989 .

[230]  S. Shimotakahara,et al.  Reaction of DNA with chemically or enzymatically activated mitomycin C: isolation and structure of the major covalent adduct. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[231]  P. Salem,et al.  Supraventricular tachycardia. A probable complication of platinum treatment. , 1984, Oncology.

[232]  S. Lipsitz,et al.  Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. , 1997, Circulation.

[233]  G. Falkson.  Multiple ventricular extrasystoles following administration of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA). , 1980, Cancer treatment reports.

[234]  T. Brown.  THE PHARMACOLOGICAL ACTIONS OF TAXINE , 1932 .

[235]  F. Ognibene,et al.  High-Dose Ifosfamide Is Associated with Severe, Reversible Cardiac Dysfunction , 1993, Annals of Internal Medicine.

[236]  Randolph P. Martin,et al.  Early anthracycline cardiotoxicity. , 1978, The American journal of medicine.

[237]  P. Weiden,et al.  Cardiotoxicity of 5-fluorouracil. , 1987, Cancer treatment reports.

[238]  J. Mason,et al.  Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy. , 1978, Cancer treatment reports.

[239]  B. Altura,et al.  Magnesium deficiency produces spasms of coronary arteries: relationship to etiology of sudden death ischemic heart disease. , 1980, Science.

[240]  R. Bukowski,et al.  Phase II trial of m-AMSA in gallbladder and cholangiocarcinoma: a Southwest Oncology Group Study. , 1983, European journal of cancer & clinical oncology.

[241]  D. V. Hoff,et al.  Cancer chemotherapy handbook , 1980 .

[242]  G. Hortobagyi,et al.  Adriamycin and mitomycin C: possible synergistic cardiotoxicity. , 1978, Cancer treatment reports.

[243]  F. Waagstein,et al.  A new insight into adriamycin-induced cardiotoxicity. , 1990, International journal of cardiology.

[244]  E. Henderson,et al.  High dose daunorubicin (NSC-83142) in the treatment of advanced acute myelogenous leukemia. , 1972, Cancer chemotherapy reports.

[245]  F. Arcamone,et al.  Synthesis, antitumor activity, and cardiac toxicity of new 4-demethoxyanthracyclines. , 1983, Cancer treatment reports.

[246]  J. Gutterman,et al.  Clinical evaluation of toxic effects of cis-diamminedichloroplatinum (NSC-119875)--phase I clinical study. , 1973, Cancer chemotherapy reports.

[247]  H. Gibbs,et al.  Late doxorubicin‐associated cardiotoxicity in children , 1994, Cancer.

[248]  G. Falkson,et al.  Amsacrine cardiotoxicity: assessment of ventricular function by radionuclide angiography. , 1983, Cancer treatment reports.

[249]  J. Krischer,et al.  Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[250]  M. Grever,et al.  Cardiac complications observed in elderly patients following 2′‐deoxycoformycin therapy , 1991, American journal of hematology.

[251]  R. Kernoff,et al.  Acute and Chronic Cardiovascular Effects of Doxorubicin in the Dog: The Cardiovascular Pharmacology of Drug‐Induced Histamine Release , 1980, Journal of cardiovascular pharmacology.

[252]  P. Wiernik,et al.  Review of amsacrine, an investigational antineoplastic agent. , 1982, Clinical pharmacy.

[253]  F. Torti,et al.  Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. , 1983, Annals of internal medicine.

[254]  M. Brambilla,et al.  Possible enhancement of the cardiotoxicity of doxorubicin when combined with mitomycin C , 1985, Medical oncology and tumor pharmacotherapy.

[255]  S. Balcerzak,et al.  Cardiac evaluation of mitoxantrone. , 1983, Cancer treatment reports.

[256]  H. Greinix,et al.  Non-Q-wave myocardial infarction associated with bleomycin and etoposide chemotherapy. , 1991, European heart journal.

[257]  R. Donehower,et al.  Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion. , 1986, Cancer treatment reports.

[258]  G. Bodey,et al.  Cardiorespiratory toxicity due to miconazole. , 1980, Annals of internal medicine.

[259]  E K Rowinsky,et al.  Sequences of taxol and cisplatin: a phase I and pharmacologic study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[260]  J. Colebatch,et al.  Daunorubicin. Results in childhood leukaemia. , 1972, Archives of disease in childhood.

[261]  A. Rosowsky,et al.  Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[262]  R. Schwartz,et al.  Interstitial pulmonary fibrosis following busulfan therapy. , 1961, The American journal of medicine.

[263]  F. Cavalli,et al.  Phase II study of amsacrine in solid tumors: a report of the EORTC Early Clinical Trial-Group. , 1983, European journal of cancer & clinical oncology.

[264]  Mushlin Ps,et al.  Anthracycline cardiotoxicity: new insights. , 1988 .

[265]  V. Zales,et al.  Endocarditis, pericarditis, and myocarditis. , 1997, Pediatric annals.

[266]  V. Devita,et al.  Heart in malignant lymphoma (Hodgkin's disease, lymphosarcoma, reticulum cell sarcoma and mycosis fungoides). A study of 196 autopsy cases. , 1968, The American journal of cardiology.

[267]  R. Sylvester,et al.  Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. , 1987, European journal of cancer & clinical oncology.

[268]  F. Muggia,et al.  Apparent myocardial ischemia associated with vinblastine administration. , 1986, Cancer treatment reports.

[269]  J. Verweij,et al.  A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C , 1988, Medical oncology and tumor pharmacotherapy.

[270]  P. Steinherz,et al.  Cardiac abnormalities after AMSA administration. , 1982, Cancer treatment reports.

[271]  J. Vannetzel,et al.  Myocardial ischemia and infarction associated with vinorelbine. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[272]  J. Pitha,et al.  A clinicopathologic analysis of adriamycin cardiotoxicity , 1973, Cancer.

[273]  G. Decorti,et al.  Amelioration of 4'-epidoxorubicin-induced cardiotoxicity by sodium cromoglycate. , 1989, European journal of cancer & clinical oncology.

[274]  W. Frishman,et al.  Cardiovascular toxicity with cancer chemotherapy. , 1997, Current problems in cardiology.

[275]  J. Hokanson,et al.  Ifosfamide in the treatment of extensive non-oat cell carcinoma of the lung. , 1982, Seminars in oncology.

[276]  R. Gilmore,et al.  Intracranial hemorrhage and focal seizures secondary to use of L-asparaginase during induction therapy of acute lymphocytic leukemia. , 1980, The Journal of pediatrics.

[277]  E. Shpall,et al.  Myocardial ischemia associated with high‐dose carmustine infusion , 1991, Cancer.

[278]  Ferrans Vj.  Overview of cardiac pathology in relation to anthracycline cardiotoxicity. , 1978, Cancer treatment reports.

[279]  L. Dirix,et al.  Neoadjuvant and adjuvant therapy for invasive bladder tumors. , 1991, European journal of cancer.

[280]  A. Weiss,et al.  Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. , 1976, Cancer treatment reports.

[281]  J. Turk,et al.  Effects of adriamycin, 4-hydroperoxycyclophosphamide and ASTA Z 7557 (INN mafosfamide) on the release of IL-2 and IL-1 in vitro. , 1987, International journal of immunopharmacology.

[282]  J. Mason,et al.  Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. , 1981, American heart journal.

[283]  R. M. Green,et al.  Human autopsy tissue concentrations of mitoxantrone. , 1986, Cancer treatment reports.

[284]  G. Blijham,et al.  Angina pectoris associated with infusions of 5-FU and vindesine. , 1986, Cancer treatment reports.

[285]  P. Smith,et al.  Functional myocardial impairment in children treated with anthracyclines for cancer , 1991, The Lancet.

[286]  T. Salmi,et al.  Vincristine treatment of acute lymphoblastic leukemia induces transient autonomic cardioneuropathy , 1989, Cancer.

[287]  L. Vaickus,et al.  Pericarditis induced by high-dose cytarabine therapy. , 1984, Archives of internal medicine.

[288]  M. Billingham,et al.  Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals. , 1978, JAMA.

[289]  R. Livingston,et al.  Small-cell carcinoma of the lung: combined chemotherapy and radiation: a Southwest Oncology Group study. , 1978, Annals of internal medicine.

[290]  D. Harrison,et al.  Histamine provocation of clinical coronary artery spasm: implications concerning pathogenesis of variant angina pectoris. , 1981, American heart journal.

[291]  K. Hermansen,et al.  Cardiotoxic effects and the influence on the beta-adrenoceptor function of doxorubicin (Adriamycin) in the rat. , 1989, Pharmacology & toxicology.

[292]  M. Spaulding,et al.  5-FU cardiotoxicity. , 1981, Cancer treatment reports.

[293]  C. Angeletti,et al.  [The evaluation of the cardiotoxicity of 4'-epidoxorubicin at high doses]. , 1991, Cardiologia.

[294]  J. Mason,et al.  Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. , 1978, Annals of internal medicine.

[295]  N. Geller,et al.  A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[296]  E. Macewen,et al.  In vitro and in vivo effect of doxorubicin combined with liposome-encapsulated muramyl tripeptide on canine monocyte activation. , 1993, Cancer research.

[297]  S. Colan,et al.  Limitations of fractional shortening as an index of contractility in pediatric patients infected with human immunodeficiency virus. , 1994, The Journal of pediatrics.